MedTech Terms
    The authoritative reference
    All terms
    CommercializationHospital Buyer & Reimbursement

    Label Claims

    Statements about a medical device's purpose, performance or benefits, subject to applicable labeling and intended-use requirements.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Label claims are statements in medical device labeling describing intended use, indications, performance or benefits. Their regulatory significance depends on the device, evidence and applicable pathway. Not every device or individual labeling statement has been reviewed and cleared or approved by FDA. Claims must be assessed against applicable labeling requirements and, where required, the device's clearance, approval or other authorization. Advertising and related circumstances can also be evidence of intended use under 21 CFR 801.4. A device exempt from premarket notification is not exempt from all labeling obligations, and a claim should not imply FDA endorsement that the device does not have.
    What the regulation says
    21 CFR 801.4 addresses objective intent, which can be shown by labeling claims, advertising, statements and circumstances of distribution. It also provides that knowledge alone of a healthcare provider's off-label use does not automatically establish a manufacturer's new intended use. Premarket review requirements vary by device and exemption limitations. This is why 'label claim' is not synonymous with 'FDA-approved claim.' Assess intended use, required authorization and labeling evidence together; the rule does not supply a blanket determination for every promotional communication.

    What this means in practice

    Review a label claim as a specific statement, not just a slogan. Identify the proposed purpose, patient population, user, use environment, endpoint and any operating conditions or limitations. Compare that statement with intended use, indications for use and the device's applicable authorization or exemption. For a performance statement such as 'detects a condition earlier,' ask: earlier than what comparator, in which population, using which endpoint and under which conditions? A bench result does not automatically demonstrate a clinical benefit. Keep the evidence, limitations and wording together in a claims review so the statement does not promise more than the study supports. Review the instructions for use, packaging, website, sales materials and demonstrations together for consistent messaging. Regulatory, quality, clinical and commercial teams can maintain a claim-to-evidence record and escalate proposed changes for the applicable intended-use and submission analysis. This is an illustrative review method, not a determination that a particular claim is lawful.

    Examples

    • Illustrative example: a team checks whether a proposed performance statement is supported by testing and consistent with the device's applicable labeling and authorization.
    • Illustrative example: a manufacturer reviews a proposed new-use advertisement for intended-use and submission implications before distributing it.

    Use cases

    1 scenario
    1

    Assessing a proposed performance statement

    Regulatory and clinical teams

    A team proposes a faster-detection claim. It identifies the comparator, population, study endpoint and limitations, then compares the proposed wording with its intended use and available evidence.

    OutcomeA documented claim-to-evidence decision, with unresolved regulatory questions referred for qualified review.
    Common pitfalls
    • •Treating all claims as individually FDA-approved.
    • •Using a performance result from one population to promise benefit in a different population.
    • •Leaving a comparator, endpoint or important limitation out of a benefit claim.
    • •Allowing advertising and instructions for use to describe different intended purposes.
    • •Assuming an exemption from premarket notification removes labeling obligations.

    Frequently asked questions

    No. Premarket review requirements vary, including devices exempt from 510(k) subject to exemption limitations. Claims still need to satisfy applicable labeling and intended-use requirements; clearance is not a universal prerequisite for every statement.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Latest in MedTech

    Sources

    4 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Official-source claim check:

    Claims and objective intended use are distinguished from FDA clearance or approval; not all devices or claims receive individual premarket review.

    Partial review: verified corrections are applied, but this is not a full accuracy certification. The last full review date is unchanged.

    Remaining verification limits
    • Checked 21 CFR 801.4 and FDA labeling context, not every device-specific exemption or promotional scenario.
    Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 2
    Link health: 3 verified 1 unchecked· last checked 2026-06-20· added official documents checked 2026-11-01
    AdvaMed·1AHRMM·1FDA·1US official source·1
    1. 1
      AdvaMed Code of Ethics
      Tier 4 Verified
      AdvaMedadvamed.org
    2. 2
      AHRMM - Healthcare Supply Chain
      Tier 4 Verified
      AHRMMahrmm.org
    3. 3
      Device Labeling
      Tier 2 Verified
      FDAfda.gov
    4. 4
      21 CFR 801.4, meaning of intended uses
      Tier 1 Unchecked
      US official sourceecfr.gov

    Inline markers like [1] jump to the matching reference above.